@article {11386,
	title = {Current trends in molecular diagnostics of chronic myeloid leukemia},
	journal = {Leukemia \& Lymphoma},
	year = {2016},
	pages = {1-14},
	abstract = {<p>Nearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.</p>
},
	url = {http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1265116},
	author = {Raquel Vinhas and Cordeiro, Milton and Pedro Pedrosa and Alexandra R. Fernandes and Pedro V. Baptista}
}
